465 related articles for article (PubMed ID: 35593668)
1. Tirzepatide - a dual GIP/GLP-1 receptor agonist - a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes.
Nowak M; Nowak W; Grzeszczak W
Endokrynol Pol; 2022; 73(4):745-755. PubMed ID: 35593668
[TBL] [Abstract][Full Text] [Related]
2. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
Fisman EZ; Tenenbaum A
Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
[TBL] [Abstract][Full Text] [Related]
3. Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes.
Frías JP
Expert Rev Endocrinol Metab; 2020 Nov; 15(6):379-394. PubMed ID: 33030356
[TBL] [Abstract][Full Text] [Related]
4. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.
Nauck MA; D'Alessio DA
Cardiovasc Diabetol; 2022 Sep; 21(1):169. PubMed ID: 36050763
[TBL] [Abstract][Full Text] [Related]
5. Incretin hormones and type 2 diabetes.
Nauck MA; Müller TD
Diabetologia; 2023 Oct; 66(10):1780-1795. PubMed ID: 37430117
[TBL] [Abstract][Full Text] [Related]
6. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
Heise T; Mari A; DeVries JH; Urva S; Li J; Pratt EJ; Coskun T; Thomas MK; Mather KJ; Haupt A; Milicevic Z
Lancet Diabetes Endocrinol; 2022 Jun; 10(6):418-429. PubMed ID: 35468322
[TBL] [Abstract][Full Text] [Related]
7. The importance of glucose-dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide.
Gasbjerg LS; Rosenkilde MM; Meier JJ; Holst JJ; Knop FK
Diabetes Obes Metab; 2023 Nov; 25(11):3079-3092. PubMed ID: 37551549
[TBL] [Abstract][Full Text] [Related]
8. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
Coskun T; Sloop KW; Loghin C; Alsina-Fernandez J; Urva S; Bokvist KB; Cui X; Briere DA; Cabrera O; Roell WC; Kuchibhotla U; Moyers JS; Benson CT; Gimeno RE; D'Alessio DA; Haupt A
Mol Metab; 2018 Dec; 18():3-14. PubMed ID: 30473097
[TBL] [Abstract][Full Text] [Related]
9. Tirzepatide: A Dual Glucose-dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Agonist for the Management of Type 2 Diabetes Mellitus.
Wong E; Cope R; Dima L; Nguyen T
Am J Ther; 2023 Jan-Feb 01; 30(1):e26-e35. PubMed ID: 36516422
[TBL] [Abstract][Full Text] [Related]
10. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists.
Urva S; Coskun T; Loghin C; Cui X; Beebe E; O'Farrell L; Briere DA; Benson C; Nauck MA; Haupt A
Diabetes Obes Metab; 2020 Oct; 22(10):1886-1891. PubMed ID: 32519795
[TBL] [Abstract][Full Text] [Related]
11. [Focus on tirzepatide, a dual unimolecular GIP-GLP-1 receptor agonist in type 2 diabetes].
Scheen AJ; Radermecker RP; Paquot N
Rev Med Suisse; 2022 Aug; 18(792):1539-1544. PubMed ID: 36004653
[TBL] [Abstract][Full Text] [Related]
12. Current findings on the efficacy of incretin-based drugs for diabetic kidney disease: A narrative review.
Mima A; Nomura A; Fujii T
Biomed Pharmacother; 2023 Sep; 165():115032. PubMed ID: 37331253
[TBL] [Abstract][Full Text] [Related]
13. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.
Karagiannis T; Avgerinos I; Liakos A; Del Prato S; Matthews DR; Tsapas A; Bekiari E
Diabetologia; 2022 Aug; 65(8):1251-1261. PubMed ID: 35579691
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: An update including recently developed glucagon-like peptide-1 (GLP-1) receptor agonists and the glucose-dependent insulinotropic polypeptide/GLP-1 receptor co-agonist tirzepatide.
Nauck MA; Mirna AEA; Quast DR
Diabetes Obes Metab; 2023 May; 25(5):1361-1371. PubMed ID: 36700380
[TBL] [Abstract][Full Text] [Related]
15. Tirzepatide: First Approval.
Syed YY
Drugs; 2022 Jul; 82(11):1213-1220. PubMed ID: 35830001
[TBL] [Abstract][Full Text] [Related]
16. The new dual gastric inhibitory peptide/glucagon-like peptide 1 agonist tirzepatide in type 2 diabetes: Is the future bright?
Papachristou S; Popovic DS; Papanas N
Diabetes Metab Res Rev; 2021 Nov; 37(8):e3503. PubMed ID: 34626443
[TBL] [Abstract][Full Text] [Related]
17. Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review.
Chavda VP; Ajabiya J; Teli D; Bojarska J; Apostolopoulos V
Molecules; 2022 Jul; 27(13):. PubMed ID: 35807558
[TBL] [Abstract][Full Text] [Related]
18. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes.
Thomas MK; Nikooienejad A; Bray R; Cui X; Wilson J; Duffin K; Milicevic Z; Haupt A; Robins DA
J Clin Endocrinol Metab; 2021 Jan; 106(2):388-396. PubMed ID: 33236115
[TBL] [Abstract][Full Text] [Related]
19. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.
Willard FS; Douros JD; Gabe MB; Showalter AD; Wainscott DB; Suter TM; Capozzi ME; van der Velden WJ; Stutsman C; Cardona GR; Urva S; Emmerson PJ; Holst JJ; D'Alessio DA; Coghlan MP; Rosenkilde MM; Campbell JE; Sloop KW
JCI Insight; 2020 Sep; 5(17):. PubMed ID: 32730231
[TBL] [Abstract][Full Text] [Related]
20. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity.
Gallwitz B
Front Endocrinol (Lausanne); 2022; 13():1004044. PubMed ID: 36313764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
